Arch Biopartners, Inc. logo

Arch Biopartners, Inc.

Arch has a diverse portfolio that includes AB569, a potential new drug for
antibiotic resistant bacterial infections in the lungs and urinary tract (TSXV:ARCH) Arch Biopartners (ACH) is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs, including cancer and infectious disease.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://archbiopartners.com
Disease Focus
Development Stage
STOCK CODECVE: ARCH
Address
545 King Street West, Ontario M5V 1M1
Toronto
Canada
Email
Contact Number
+1 647 428 7031

Arch Biopartners (ACH) is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs, including cancer and infectious disease.

In 2010, Arch acquired the commercial rights to the brain tumour targeting and peptide-solid surface technology platforms. The lead inventors of MetaMx are Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn at the University of Calgary.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/arch-biopartners-inc-foiff-” connections=”true” suffix=””]

Arch Biopartners lead technology molecules MetaMxŽ is a library of unique peptides designed specifically to target brain tumour initiating cells (BTICs).

March 2018, Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing.

In Feb 2015, Arch Biopartners was listed on the TSX Venture Exchange (TSXV) under the trading symbol ´ACH.